Researchers at USC [University of Southern California] have utilized stem cells to track neuronal growth and identify specific genes that appear to be responsible for the development of schizophrenia, bipolar disorder and depression. The study linked the DISC1 gene to the development of schizophrenia, which currently does not have effective treatments and causes disproportionate disability compared to other neurological disorders. Like many neurological disorders, the source of schizophrenia has been ambiguous and this research, with the use of stem cells, is helping to navigate this disorder. Through the utilization of stem cells, the study determined how genes like DISC1 function in the body, and their downstream impact on protein function and neurotransmitter production by tracking the gene expression.
Researchers at UC Davis have created lab-grown brain organoids that are complex and vascularized, dramatically furthering research for brain disorders. Given that the human brain is one of the most complex anatomical structures and researchers are still discovering new functions and neuronal pathways, having brain organoids in vitro greatly expedites this research. When several small brain organoids joined together, researchers observed nerve impulses among the structures, signifying cellular communication that resembles that of fully-grown human brains. In a recent development, these organoids have vascularized and have brought researchers one step closer to both understanding neurological disorders, as well as helping patients replace damaged neurons from conditions like strokes, Alzheimer’s etc.
A $225m investment from pharmaceutical giant Bayer catapults BlueRock Therapeutics onto the stem cell therapy stage. BlueRock will initially focus on cardiovascular and neurological treatments. A team led by Dr. Michael Laflamme and Dr. Gordon Keller will concentrate on regenerating heart muscle for patients who have suffered a heart attack, whilst a team led by Dr. Lorenz Studer and Dr. Viviane Tabar will concentrate on restoring dopamine-producing cells in patients with Parkinson's disease .